Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $13.14 Average PT from Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned an average rating of “Hold” from the twelve analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $13.1429.

Several equities analysts have weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Tuesday, April 21st. Royal Bank Of Canada set a $3.00 target price on Jasper Therapeutics and gave the company a “sector perform” rating in a report on Friday, May 15th. TD Cowen lowered Jasper Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Finally, UBS Group assumed coverage on Jasper Therapeutics in a report on Monday, March 23rd. They set a “neutral” rating on the stock.

Jasper Therapeutics Trading Down 1.8%

Shares of NASDAQ:JSPR opened at $0.46 on Wednesday. Jasper Therapeutics has a 1 year low of $0.42 and a 1 year high of $7.19. The business has a fifty day simple moving average of $0.81 and a 200 day simple moving average of $1.26. The firm has a market cap of $12.81 million, a price-to-earnings ratio of -0.14 and a beta of 3.00.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.08. On average, sell-side analysts forecast that Jasper Therapeutics will post -1.81 EPS for the current year.

Hedge Funds Weigh In On Jasper Therapeutics

Several institutional investors have recently bought and sold shares of JSPR. Goldman Sachs Group Inc. raised its holdings in Jasper Therapeutics by 6,394.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after buying an additional 1,719,602 shares in the last quarter. Acorn Capital Advisors LLC acquired a new stake in shares of Jasper Therapeutics in the third quarter valued at about $3,291,000. Velan Capital Investment Management LP grew its position in shares of Jasper Therapeutics by 86.1% in the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock valued at $6,206,000 after purchasing an additional 1,234,567 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of Jasper Therapeutics in the third quarter valued at about $2,475,000. Finally, Propel Bio Management LLC acquired a new stake in shares of Jasper Therapeutics in the third quarter valued at about $2,449,000. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.